Fintel reports that on April 29, 2024, TD Cowen initiated coverage of Geron (NasdaqGS:GERN) with a Buy recommendation.
Analyst Price Forecast Suggests 25.24% Upside
As of April 16, 2024, the average one-year price target for Geron is 5.18. The forecasts range from a low of 4.54 to a high of $6.30. The average price target represents an increase of 25.24% from its latest reported closing price of 4.14.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Geron is 109MM, an increase of 45,942.19%. The projected annual non-GAAP EPS is -0.20.
What is the Fund Sentiment?
There are 356 funds or institutions reporting positions in Geron. This is an decrease of 10 owner(s) or 2.73% in the last quarter. Average portfolio weight of all funds dedicated to GERN is 0.13%, an increase of 6.08%. Total shares owned by institutions increased in the last three months by 6.17% to 410,880K shares. 
The put/call ratio of GERN is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 46,202K shares representing 7.85% ownership of the company. No change in the last quarter.
Deep Track Capital holds 29,583K shares representing 5.02% ownership of the company. In its prior filing, the firm reported owning 25,700K shares , representing an increase of 13.13%. The firm decreased its portfolio allocation in GERN by 0.87% over the last quarter.
Vivo Capital holds 27,225K shares representing 4.62% ownership of the company. In its prior filing, the firm reported owning 24,144K shares , representing an increase of 11.32%. The firm increased its portfolio allocation in GERN by 69.26% over the last quarter.
TCG Crossover Management holds 23,376K shares representing 3.97% ownership of the company. No change in the last quarter.
NEA Management Company holds 22,776K shares representing 3.87% ownership of the company. No change in the last quarter.
Geron Background Information
(This description is provided by the company.)
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
Click to Learn More
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
